Monocyte Soluble Activation Markers sCD14 and sCD163 in Children With Type 1 Diabetes Mellitus

NCT ID: NCT05347836

Last Updated: 2022-04-26

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 90 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2022-07-01
• Study Completion Date: 2023-08-01

Brief Summary

The study aims to compare serum levels of sCD14 and sCD163 in children with type 1 Diabetes Mellitus with healthy controls, study the distribution of monocyte subsets in children with T1DM , correlate monocyte subsets and their soluble activation markers sCD14 and sCD163 with parameters reflecting islet β-cell insufficiency in children with T1DM.

Detailed Description

Type 1 diabetes mellitus (T1DM) is T-cell mediated autoimmune disease in which the function of insulin-secreting pancreatic β-cells is impaired due to autoreactive immune cell-mediated destruction (insulitis). Although adaptive immunity has always been the focus for scientists in studying the pathogenesis of T1DM, yet, innate immunity also plays a critical role. Alterations in innate immune responses drive autoimmune pathogenesis, with involvement in the initial break in tolerance and the later failure of regulation. Several studies suggest that the development of T1DM is strongly associated with different immune cells, including monocytes. Specifically, an increase in the monocyte population has been shown to trigger β-cell destruction during insulitis. Intermediate monocytes may serve as M2 macrophage precursors with high anti-inflammatory properties, producing IL-10. However, other studies reported them to have an antigen-presenting function with a dendritic cell-like feature. Upon antigen stimulation, they became the main producers of inflammatory factors, like TNF-α which has been shown to correlate with the severity of T1DM. Activation of circulating monocytes to a pro-inflammatory state induces the shedding of membrane bound CD14 (mCD14) to soluble CD14. Compared to other acute phase proteins, sCD14 was found to be the most sensitive in T1DM. Soluble CD163 is present in blood serum as a result of shedding the CD163 membrane form of activated monocyte-macrophage-lineage cells in the course of inflammation. Plasma sCD163 is widely used as an immunomodulator with anti-inflammatory properties. It was found to be increased in T2DM.

Conditions

Type1diabetes

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: RETROSPECTIVE

Study Groups

Children diagnosed to have T1DM with a minimum duration of five years

ELISA

Intervention Type: DIAGNOSTIC_TEST

Determination of serum levels of sCD14 and sCD163 using ELISA

Healthy children

ELISA

Intervention Type: DIAGNOSTIC_TEST

Determination of serum levels of sCD14 and sCD163 using ELISA

Interventions

ELISA

Determination of serum levels of sCD14 and sCD163 using ELISA

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Inclusion Criteria

• Children of any age and sex diagnosed with T1DM (according to WHO criteria) with a minimum duration of five years will be included.

Exclusion Criteria

• Children with other with coexisting autoimmune, chronic, and acute inflammatory diseases.

• Minimum Eligible Age: 5 Years
• Maximum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Assiut University

OTHER

Sponsor Role: lead

Responsible Party

Nada Maher Mokhtar Ahmed

Doctor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Central Contacts

Nada M Mokhtar, MD

Role: CONTACT

nadamaher94@aun.edu.eg

+201501149921

Nahla M Elsherbiny, MD

Role: CONTACT

nahlaelsherbiny@aun.edu.eg

+20 106 7150105

References

Ismail NA, Abd El Baky AN, Ragab S, Hamed M, Hashish MA, Shehata A. Monocyte chemoattractant protein 1 and macrophage migration inhibitory factor in children with type 1 diabetes. J Pediatr Endocrinol Metab. 2016 Jun 1;29(6):641-5. doi: 10.1515/jpem-2015-0340.

Reference Type: BACKGROUND

PMID: 27054595 (View on PubMed)

Morgan NG, Leete P, Foulis AK, Richardson SJ. Islet inflammation in human type 1 diabetes mellitus. IUBMB Life. 2014 Nov;66(11):723-34. doi: 10.1002/iub.1330. Epub 2014 Dec 11.

Reference Type: BACKGROUND

PMID: 25504835 (View on PubMed)

Kim TK, Lee MS. Innate immune receptors in type 1 diabetes: the relationship to cell death-associated inflammation. Biochem Soc Trans. 2020 Jun 30;48(3):1213-1225. doi: 10.1042/BST20200131.

Reference Type: BACKGROUND

PMID: 32510139 (View on PubMed)

Marshak-Rothstein A. Autoimmunity--promoting and stabilizing innate immunity 'UNWUCHT'. Immunol Rev. 2016 Jan;269(1):7-10. doi: 10.1111/imr.12387. No abstract available.

Reference Type: BACKGROUND

PMID: 26683141 (View on PubMed)

Mysliwska J, Smardzewski M, Marek-Trzonkowska N, Mysliwiec M, Raczynska K. Expansion of CD14+CD16+ monocytes producing TNF-alpha in complication-free diabetes type 1 juvenile onset patients. Cytokine. 2012 Oct;60(1):309-17. doi: 10.1016/j.cyto.2012.03.010. Epub 2012 Apr 7.

Reference Type: BACKGROUND

PMID: 22484242 (View on PubMed)

Ancuta P, Weiss L, Haeffner-Cavaillon N. CD14+CD16++ cells derived in vitro from peripheral blood monocytes exhibit phenotypic and functional dendritic cell-like characteristics. Eur J Immunol. 2000 Jul;30(7):1872-83. doi: 10.1002/1521-4141(200007)30:73.0.CO;2-2.

Reference Type: BACKGROUND

PMID: 10940876 (View on PubMed)

Wong KL, Tai JJ, Wong WC, Han H, Sem X, Yeap WH, Kourilsky P, Wong SC. Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood. 2011 Aug 4;118(5):e16-31. doi: 10.1182/blood-2010-12-326355. Epub 2011 Jun 7.

Reference Type: BACKGROUND

PMID: 21653326 (View on PubMed)

Harms RZ, Ostlund KR, Cabrera MS, Edwards E, Fisher M, Sarvetnick N. Confirmation and Identification of Biomarkers Implicating Environmental Triggers in the Pathogenesis of Type 1 Diabetes. Front Immunol. 2020 Sep 15;11:1922. doi: 10.3389/fimmu.2020.01922. eCollection 2020.

Reference Type: BACKGROUND

PMID: 33042112 (View on PubMed)

Laursen TL, Wong GL, Kazankov K, Sandahl T, Moller HJ, Hamilton-Dutoit S, George J, Chan HL, Gronbaek H. Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment. J Gastroenterol Hepatol. 2018 Feb;33(2):484-491. doi: 10.1111/jgh.13849.

Reference Type: BACKGROUND

PMID: 28618015 (View on PubMed)

Llaurado G, Gonzalez-Clemente JM, Maymo-Masip E, Subias D, Vendrell J, Chacon MR. Serum levels of TWEAK and scavenger receptor CD163 in type 1 diabetes mellitus: relationship with cardiovascular risk factors. a case-control study. PLoS One. 2012;7(8):e43919. doi: 10.1371/journal.pone.0043919. Epub 2012 Aug 24.

Reference Type: BACKGROUND

PMID: 22937125 (View on PubMed)

Ratajczak W, Atkinson SD, Kelly C. The TWEAK/Fn14/CD163 axis-implications for metabolic disease. Rev Endocr Metab Disord. 2022 Jun;23(3):449-462. doi: 10.1007/s11154-021-09688-4. Epub 2021 Sep 20.

Reference Type: BACKGROUND

PMID: 34542797 (View on PubMed)

Study Documents

Document Type: Study Protocol

View Document

Related Links

https://pubmed.ncbi.nlm.nih.gov/34542797/

Related Info

Other Identifiers

Monocyte activation markers

Identifier Type: -

Identifier Source: org_study_id